Congenital adrenal hyperplasia (CAH) refers to a group of genetic disorders with defects in the synthesis of cortisol. The synthesis of other steroids such as mineralocorticoids and adrenal/gonadal sex steroids may also be affected. The clinical presentation of the various forms of CAH depend on the following: (1) the affected enzyme, (2) the residual enzymatic activity, (3) the physiologic consequences of deficiencies of the end-products and excess of precursors. The first part of this two-part review discusses the genetics, biochemistry, and clinical presentation of the different forms of CAH. Understanding the genetics and pathophysiology of each of the various enzyme mutations is essential for the evaluation and management of the different clinical forms of CAH.
Get full access to this article
View all access options for this article.
References
1.
1. Stratakis CA, Rennert OM. Congenital adrenal hyperplasia: molecular genetics and alternative approaches to treatment. Clin Lab Sci.1999;36:329-363.
2.
2. Orth DN, Kovacs WJ. In: Wilson JD, Foster DW, Kronenberg HM, Larsen PR, eds. Williams Textbook of Endocrinology, 9th ed.Philadelphia: WB Saunders; 1998:517-664.
3.
3. Bose HS, Sugawara T, Strauss JF III, Miller WL. The pathophysiology and genetics of congenital lipoid adrenal hyperplasia. International Congenital Lipoid Adrenal Hyperplasia Consortium. N Engl J Med.1996;335:1870-1878.
4.
4. Kimura T, Suzuki K.Components of the electron transport system in adrenal steroid hydroxylase. Isolation and properties of non-heme iron protein (adrenodoxin). J Biol Chem.1967;242:485-491.
5.
5. Sparkes RS, Klisak I, Miller WL. Regional mapping of genes encoding human steroidogenic enzymes: P450scc to 15q23-q24, adrenodoxin to 11q22; adrenodoxin reductase to 17q24-q25; and P450c17 to IOq24-q25. DNA Cell Biol.1991;10:359-365.
6.
6. Miller WL. Why nobody has P450scc (20,22 desmoslase) deficiency. J Clin Endocrinol Metab.1998;83:1399-1400.
7.
7. Labrie F, Simard J, Luu-The V, et al. Structure and tissue-specific expression of 3 beta-hydroxysteroid dehydro-genase/5-ene-4-ene isomerase genes in human and rat classical and peripheral steroidogenic tissues. J Steroid Biochem Mol Biol.1992;41:421-435.
8.
8. Berube D, Luu-The V, Lachance Y, et al. Assignment of the human 3 beta-hydroxysteroid dehydrogenase gene (HSDB3) to the p13 band of chromo-some 1. Cytogenet Cell Genet.1989;52: 199-200.
9.
9. Morrison N, Nickson DA, McBride MW, et al. Regional chromosomal assignment of human 3-beta-hydroxy-5-ene steroid dehydrogenase to lpl3.1 by non-isotopic in situ hybridisation. Hum Genet. 1991;87:223-225.
10.
10. Fan YS, Sasi R, Lee C, et al. Localization of the human CYP17 gene (cytochrome P450 (17 alpha)) to 10q24.3 by fluorescence in situ hybridization and simultaneous chromosome banding. Genomics. 1992;14:1110-1111.
11.
11. Zhang LH, Rodriguez H, Ohno S, Miller WL. Senine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome. Proc Natl Acad Sci USA. 1995;92:10619-10623.
12.
12. Grumbach MM, Conte FA. Disorders of sex differentiation. In: Wilson JD, Foster DW, Kronenberg HM, Larsen PR, eds. Williams Textbook of Endocrinology, 9th ed.Philadelphia: WB Saunders; 1998:1303-1425.
13.
13. Chua SC, Szabo P, Vitek A, et al. Cloning of cDNA encoding steroid 11-beta-hydroxylase (P450C11). Proc Natl Acad Sci.1987;84:7193-7197.
14.
14. Mornet E, Dupont J, Vitek A, White PC. Characterization of two genes encoding human steroid 11 beta-hydroxylase (P-450(11) beta). J Biol Chem.1989;264:20961-20967.
15.
15. White PC, Curnow KM, Pascoe L.Disorders of steroid 11 beta-hydroxylase isozymes. Endocrine Rev.1994;15:421-438.
16.
16. Taymans SE, Pack S, Pak E, et al. Human CYP11B2 (aldosterone synthase) maps to chromosome 8q24.3. J Clin Endocrinol Metab.1998;83:1033-1036.
17.
17. New MI, White PC. Genetic disorders of steroid hormone synthesis and metabolism. Baillieres Clin Endocrinol Metab.1995;9:525-554.
18.
18. Krone N, Braun A, Roscher AA, et al. Predicting phenotype in steroid 21-hydroxylase deficiency? Comprehensive genotyping in 155 unrelated, well-defined patients from southern Germany. J Clin Endocrinol Metab.2000;85:1059-1065.
19.
19. Nikoshkov A, Lajic S, Holst M, et al. Synergistic effect of partially inactivating mutations in steroid 21-hydroxylase deficiency. J Clin Endocrinol Metab.1997;82:194-199.
20.
20. Saenger P.New developments in congenital lipoid adrenal hyperplasia and steroidogenic acute regulatory protein. Pediatr Clin North Am.1997;44:397-421.
21.
21. Pang S.Congenital adrenal hyperplasia. Endocrinol Metab Clin North Am.1997;26:853-891.
22.
22. Marui S, Castro M, Latronico AC, et al. Mutations in the type II 3β-hydroxysteroid dehydrogenase (HSD3B2) gene can cause premature pubarche in girls. Clin Endocrinol.2000;52:67-75.
23.
23. Biason-Lauber A, Leiberman E, Zachmann M.A single amino acid substitution in the putative redox partner-binding site of P450c17 as cause of isolated 17,20-lyase deficiency. J Clin Endocrinol Metab.1997;82:3807-3812.
24.
24. Geller DH, Auchus RJ, Mendonca BB, Miller WL. The genetic and functional basis of isolated 17,20-lyase deficiency. Nat Genet.1997;17:201-205.
25.
25. Biason-Lauber A, Kempken B, Werder E, et al. 17alpha-hydroxylase/17,20-lyase deficiency as a model to study enzymatic activity regulation: role of phosphorylation. J Clin Endocrinol Metab.2000;85:1226-1231.
26.
26. Speiser PW, Dupont B, Rubinstein P, et al. High frequency of nonclassical steroid 21-hydroxylase deficiency. Am J Hum Genet.1985;37:650-667.
27.
27. Sherman SL, Aston CE, Morton NE, et al. A segregation and linkage study of classical and nonclassical 21-hydroxylase deficiency. Am J Hum Genet.1988;42:830-838.
28.
28. Pang SY, Wallace MA, Hofman L, et al. Worldwide experience in newborn screening for classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics. 1988;81:866-874.
29.
29. Fiet J, Gueux B, Raux-Demay MC, et al. 21-deoxycortisol. A new marker of virilizing adrenal hyperplasia caused by 21-hydroxylase deficiency. Presse Med.1989;18:1965-1969.
30.
30. New MI. Diagnosis and management of congenital adrenal hyperplasia. Annu Rev Med.1998;49:311-328.
31.
31. Wedell A.An update on the molecular genetics of congenital adrenal hyperplasia: diagnostic and therapeutic aspects. J Pediatr Endocrinol Metab.1998;11:581-589.
32.
32. Levine LS, Dupont B, Lorenzen F, et al. Genetic and hormonal characterization of cryptic 21-hydroxylase deficiency. J Clin Endocrinol Metab.1981;53:1193-1198.
33.
33. Zachmann M, Tassinari D, Prader A.Clinical and biochemical variability of congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency. A study of 25 patients. J Clin Endocrinol Metab.1983;56:222-229.
34.
34. White PC, Dupont J, New MI, et al. A mutation in CYP11B1 (Arg-448→*His) associated with steroid 11 beta-hydroxylase deficiency in Jews of Moroccan origin. J Clin Invest. 1991;87:1664-1667.
35.
35. Rosler A, Leiberman E, Cohen T.High frequency of congenital adrenal hyperplasia (classic 11 beta-hydroxylase deficiency) among Jews from Morocco. Am J Med Genet.1992;42:827-834.
